ConductScience.org, home

Comparison · NCT05296629-68cb47cb

DFD-29 vs Placebo: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. DFD-29 vs Placebo: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. Trial comparisons, record NCT05296629-68cb47cb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05296629-68cb47cb

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6480.5590.727wilson
Risk in group 20.3130.2220.421wilson
Risk difference, group 1 minus group 20.3350.1960.456newcombe hybrid score
Risk ratio, group 1 over group 22.071.462.94log
Odds ratio, group 1 over group 24.042.227.37log
Number needed to treat, for one more participant with the outcome on DFD-29 than on Placebo2.982.195.11from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DFD-29DFD-29 (40 mg) extended release capsules~DFD-29: DFD-29 (40 mg) extended release capsules79122OG000
Group 2PlaceboPlacebo capsules matching DFD-29~Placebo: Placebo capsules2580OG001

Outcome

Type
PRIMARY
Title
Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.
Description
Proportion of subjects with IGA (modified scale without erythema) 'treatment success' - Grade 0 or 1 at Week 16 with at least 2 grade reduction from Baseline to Week 16, in the DFD-29 group compared to Placebo.~The modified IGA scale is a 5-point scale from Grade 0 to Grade 4, wherein Grade 0 is Clear, Grade 1 is Near Clear, Grade 2 is Mild, Grade 3 is Moderate and Grade 4 is Severe Rosacea. A lowering of the score with treatment indicates an improvement in the disease condition and a beneficial outcome.
Time frame
Baseline to Week 16.
Population
ITT population defined as, 'All randomized subjects'

Source ClinicalTrials.gov

Trial

Title
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
NCT number
NCT05296629
Phases
PHASE3
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Lead sponsor
Journey Medical Corporation
Results first posted
2024-12-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05296629-68cb47cb